Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor
Copyright 1999 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: Individuals infected with human
immunodeficiency virus type 1 (HIV-1) who are treated with highly active antiretroviral
therapy (HAART), including HIV-1 protease inhibitors, experience dramatic
benefits.1 However, virologic failure occurs
commonly in clinical trials and in practice.2,3
The CCR5Δ32 mutation is associated with decreased susceptibility to
HIV-1 infection (Δ32/Δ32) and slower progression to acquired immunodeficiency syndrome (wild
type [wt]/Δ32).4 We wished to determine whether the presence of
the CCR5Δ32 allele would affect virologic outcome after HAART is initiated.
Valdez H, Purvis SF, Lederman MM, Fillingame M, Zimmerman PA. Association of the CCR5Δ32 Mutation With Improved Response to Antiretroviral Therapy. JAMA. 1999;282(8):734. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-8-jbk0825